Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin plus Norepinephrine vs Norepinephrine in ACLF with Septic Shock and AKI
NCT06556472Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin in acute kidney injury (AKI) and septic shock (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients developing 1 stage improvement in Acute kidney injury stage with resolution of shock at Day 4. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
terlipressin
03
Conditions
acute kidney injury (AKI)septic shock
Beyond the preview
Go deeper on NCT06556472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556472.